Moberg Pharma reports positive interim results in phase II

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Dec 13, 2013 at 2:15 AM

Moberg Pharma reports positive interim results in phase II clinical study of MOB-015

Moberg Pharma AB (OMX: MOB) today announced positive interim results from its ongoing phase ll study of MOB-015. After six months of treatment with MOB-015, 40 per cent of the patients were mycologically cured and no safety concerns were identified. MOB-015 is a novel topical formulation of terbinafine for the treatment of nail fungus (onychomycosis). The purpose of the study is to confirm the product concept of MOB-015 and provide a basis for out-licensing and further clinical development. 25 patients will be treated for twelve months and followed for a total of fifteen months with respect to the endpoints that the FDA and EMA normally accept for nail fungus. The primary endpoint is the proportion of patients with mycological cure, defined as negative culture and negative KOH microscopy. The study is conducted with leading expertise in the field at Sahlgrenska University Hospital in Gothenburg, Sweden. Patient enrollment in the study was completed in May 2013 and the final results are expected second half of 2014. "These 6-month interim data are clearly promising and indicate very competitive performance of MOB-015", said Kjell Rensfeldt, VP R&D at Moberg Pharma. "We are excited to announce the interim data for MOB-015. Oral terbinafine is the gold standard for the treatment of nail fungus. If the final data follow the trajectory of the interim results for this novel topical formulation, MOB-015 has the potential to become a major advance in the treatment of nail fungus", said Peter Wolpert, CEO of Moberg Pharma. The results from the interim analysis are no guarantee that the final results at study completion will be positive. About MOB-015 and nail fungus MOB-015 is a new topical treatment for nail fungus. MOB-015 is based on Moberg Pharma's patent pending formulation technology, which in preclinical studies has been shown to transport high concentrations of terbinafine into and through nail tissue. As MOB-015 is applied locally, the safety issues associated with oral medications are avoided. Nail fungus is a common nail disease. It afflicts approximately 10 percent of the population and is more common among the elderly. The market is expected to exceed USD 1 billion. Many patients remain untreated and according to specialists in the field, there is a great need for a new topical treatment with a favorable safety profile. About this information Moberg Pharma discloses this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 8.00 am (CET) on December 13, 2013. For further information, please contact: Peter Wolpert, CEO Mobile: +46 (0)70 - 735 71 35; E-mail: peter.wolpert@mobergpharma.se (peter.wolpert@mobergderma.se) Peter Östling, IR Mobile: +46 (0)76 - 314 09 78; E-mail: peter.ostling@mobergpharma.se About Moberg Pharma Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with direct sales through its own sales organization in the US and sales through distributors in more than 40 countries. The company’s product portfolio includes topical products for the treatment of skin disorders and pain under the brands Kerasal®, Jointflex®, Kerasal Nail™ and Kaprolac®. Kerasal Nail™ (Nalox™ in many markets) is the leading product for the treatment of nail disorders in the Nordic market. The portfolio is developed further through acquisitions and in -licensing of products as well as product development with focus on innovative drug delivery based on proven compounds. Moberg Pharma has offices in Stockholm and New Jersey and the company’s share (OMX: MOB) is listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergpharma.com.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NAPCO Security's Innovative Push at ISC East 2026

NAPCO's New Showcase at ISC East 2026 Let's dive into NAPCO Security Technologies' latest development, because these folks are taking the stage at the ISC East 2026, one of the big kahunas in security trade shows. Happening on November 4th and 5th at the Jacob Javits Center, the booth near the main entrance will be the place to catch the latest from this New York outfit,...

FirstService Ups the Ante with Stylish Jacksonville Office

A New Chapter for FirstService Residential Picture this: a property management powerhouse dialing up their Jacksonville operations with a shiny new office move. FirstService Residential, North America's big shot in property management, has swapped location to a swish setup on Southpoint Drive South in Jacksonville, Florida, aiming to supercharge collaboration and give a...

York Space Systems Faces Critical Lawsuit Deadline

Turbulence in the Satellite Markets When York Space Systems launched its flashy IPO earlier this year, investors lined up in droves, eyes gleaming at the promise of satellite-driven riches. But now, it feels like that promising start shattered faster than a cheap rocket. York, known for its bread-and-butter reliance on federal contracts, primarily with the U.S. Department...

Rising Demand for Natural Fibres: Woolmark's Bold Move

A Shift Toward Nature-Driven Choices There's something brewing in the fashion world that signals a deeper shift—a movement toward fibers that feel real, fibers that nature and time have refined. Recent Ipsos research commissioned by Woolmark has laid bare the growing consumer preference across major markets, with a distinct swing towards natural fibers, leaving...

Proxy Season 2026: Proposals Drop But Support Rises

An Unexpected Twist in Proxy Season The corporate governance scene for 2026's proxy season has thrown its share of curveballs. Shareholders are rallying their support behind proposals, even as the volume of those proposals tumble like a bad penny drop. Broadridge's recent ProxyPulse report shakes up the scene, getting us all to take a closer look at what's really...

Data Center Piping Surges With AI Cooling to $4.5B

Liquid Cooling Revolutionizes Data Center Infrastructure Gotta hand it to the tech world, when it decides to shift, it shifts hard and fast. The data center piping market isn't just keeping up—it's sprinting. The move towards liquid-cooled AI setups isn’t just a trend; it’s a defining transformation. With a projected explosion to a $4.5 billion market by 2035, you...

Elanco's Strategic Shift: Jamie Preston Takes the Helm

Elanco's Bold HR Transition: A New Leader Steps Up Well, here's a shake-up that might just turn a few heads in the corporate world. Elanco Animal Health, the outfit with the ticker NYSE:ELAN that many have their eyes on, is shuffling its HR deck, bringing in Jamie Preston from Eli Lilly to take charge as the new Chief People Officer. Mark November 3rd on your calendars;...

Revolutionizing Textiles: Touchscreen Garments Emerge

Picture a world where your shirt does more than just cover your back. Bingo, folks—smart textiles have taken center stage with groundbreaking technology that melds touchscreens with fabric, and the brains behind it hail from the National University of Singapore (NUS). It's not just about slapping a few LEDs onto a vest. We're talking about clothing that can display...

Prospanica Summit 2026: Envisioning More Opportunities Ahead

The Road to Envisioning 'Más': A Dive into the Future Let's break down what's ahead with the 2026 Prospanica Summit—a collision of ambition and opportunity set to strike at Marina Del Rey. It's a Saturday—November 7th to be exact—when all this goes down, aiming to shake up the aspirations of Hispanic MBAs and business pros from coast to coast. Think MBAs,...

Cystic Fibrosis Market: Emerging Therapies Boost Growth

The landscape of cystic fibrosis treatment is on the cusp of a seismic shift, promising new therapies poised to redefine patient care and market dynamics. As we stand at the intersection of innovation and opportunity, the impending transformation is fueled by groundbreaking therapies, increased healthcare spending, and a stronger push for personalized medicine. The Winds...